| Literature DB >> 30381844 |
Lisa R Bartner1, Stephanie McGrath1, Adam Drury1, Annie V Chen2, Arianne Morris1, Melissa Brewer1, Meri Hall2, Michael R Lappin1.
Abstract
BACKGROUND: Neurobartonellosis occurs in people. The role these organisms might play in inflammatory brain disease of dogs is unclear. HYPOTHESIS/Entities:
Keywords: PCR; bartonellosis; encephalomyelitis; meningitis; protozoal
Mesh:
Substances:
Year: 2018 PMID: 30381844 PMCID: PMC6271302 DOI: 10.1111/jvim.15288
Source DB: PubMed Journal: J Vet Intern Med ISSN: 0891-6640 Impact factor: 3.333
MRI and CSF distribution
| Sex | Age | MRI localization | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Category | (n) | Male | Female | Range | Median | Multifocal | Focal | Normal | No imaging |
| Lymphocytic pleocytosis – CO | 10 | 6 | 4 | 0.8‐10 | 6 | 5 | 3 | 1 | 1 |
| Mixed pleocytosis – CO | 10 | 3 | 7 | 0.2‐12 | 7 | 5 | 2 | 3 | 0 |
| Mononuclear pleocytosis – CO | 1 | 1 | 0 | 10 | NA | 0 | 0 | 1 | 0 |
| Neutrophilic pleocytosis – CO | 1 | 0 | 1 | 6 | NA | 0 | 0 | 1 | 0 |
| Undifferentiated pleocytosis – CO | 1 | 1 | 0 | 3 | NA | 1 | 0 | 0 | 0 |
| All inflammatory combined – CO | 23 | 11 | 12 | 0.2‐12 | 6 | 11 | 5 | 6 | 1 |
| Lymphocytic pleocytosis – WA | 21 | 10 | 11 | 0.67‐12 | 4 | 8 | 7 | 4 | 2 |
| Mixed pleocytosis – WA | 11 | 5 | 6 | 1.0‐8 | 6 | 5 | 1 | 4 | 1 |
| Mononuclear pleocytosis – WA | 6 | 3 | 3 | 0.33‐11 | 7 | 1 | 3 | 0 | 2 |
| Neutrophilic pleocytosis – WA | 3 | 2 | 1 | 0.5‐8 | 5 | 2 | 0 | 0 | 1 |
| Eosinophilic pleocytosis – WA | 1 | 1 | 0 | 2 | 1 | 0 | 0 | ||
| All inflammatory combined – WA | 42 | 21 | 21 | 0.5‐12 | 5 | 17 | 11 | 8 | 4 |
| All inflammatory combined – CO and WA | 65 | 32 | 33 | 0.2‐12 | 11 | 28 | 16 | 14 | 7 |
| Noninflammatory – CO | 33 | 23 | 10 | 0.25‐13 | 8 | ||||
| Noninflammatory – WA | 74 | 42 | 32 | 0.17‐15 | 8 | ||||
| All noninflammatory – CO and WA | 107 | 65 | 42 | 0.17‐15 | 8 | 16 | 55 | 7 | 29 |
Distribution of CSF and MRI results from dogs suspected as having inflammatory CNS disease. MRI, magnetic resonance imaging.
Demographics of dogs with and without inflammatory CNS disease
| Inflammatory group (n = 65) | Noninflammatory group (n = 107) | |
|---|---|---|
| Neuroanatomic localization | 30 (46.2%) | 23 (21.5%) |
| Multifocal | 13 (20.0%) | 37 (34.6%) |
| Brain | 15 (23.1%) | 33 (30.8%) |
| Spine | 7 (10.8%) | 5 (4.7%) |
| Normal exam | 0 | 4 (3.7%) |
| Neuromuscular | 0 | 5 (4.7%) |
| Not available | ||
| T2W hyperintensities on MRI | 29 (49.2%) | 16 (15.0%) |
| Multifocal | 8 (13.6%) | 23 (21.5%) |
| Brain | 7 (11.9%) | 26 (24.3%) |
| Spine | 15 (25.4%) | 29 (27.1%) |
| Normal exam | 6 (9.2%) | 7 (6.5%) |
| Not available | 0 | 6 (5.6%) |
| Extraparenchymal | ||
| GC administered before MRI/CSF | 14 (21.5%) | 21 (19.6%) |
| Yes | 39 (60.0%) | 81 (75.7%) |
| No | 12 (18.5%) | 5 (4.7%) |
| Unknown history | ||
| Total dogs | 65 | 107 |
Glucocorticoid administration before MRI and CSF, neuroanatomic localization, and T2W hyperintensities on MRI in dogs with and without inflammatory CNS disease. CSF, cerebrospinal fluid; GC, glucocorticoids; MRI, magnetic resonance imaging; T2W, T2 weighted.